Literature DB >> 20826577

Baseline inhibin B and anti-Mullerian hormone measurements for diagnosis of hypogonadotropic hypogonadism (HH) in boys with delayed puberty.

Régis Coutant1, Estelle Biette-Demeneix, Claire Bouvattier, Natacha Bouhours-Nouet, Frédérique Gatelais, Sylvie Dufresne, Stéphanie Rouleau, Najiba Lahlou.   

Abstract

CONTEXT: The diagnosis of isolated hypogonadotropic hypogonadism (IHH) in boys with delayed puberty is challenging, as may be the diagnosis of hypogonadotropic hypogonadism (HH) in boys with combined pituitary hormone deficiency (CPHD). Yet, the therapeutic choices for puberty induction depend on accurate diagnosis and may influence future fertility.
OBJECTIVE: The aim was to assess the utility of baseline inhibin B (INHB) and anti-Mullerian hormone (AMH) measurements to discriminate HH from constitutional delay of puberty (CDP). Both hormones are produced by Sertoli cells upon FSH stimulation. Moreover, prepubertal AMH levels are high as a reflection of Sertoli cell integrity. PATIENTS: We studied 82 boys aged 14 to 18 yr with pubertal delay: 16 had IHH, 15 congenital HH within CPHD, and 51 CDP, as confirmed by follow-up. Subjects were genital stage 1 (testis volume<3 ml; 9 IHH, 7 CPHD, and 23 CDP) or early stage 2 (testis volume, 3-6 ml; 7 IHH, 8 CPHD, and 28 CDP).
RESULTS: Age and testis volume were similar in the three groups. Compared with CDP subjects, IHH and CPHD subjects had lower INHB, testosterone, FSH, and LH concentrations (P<0.05), whereas AMH concentration was lower only in IHH and CPHD subjects with genital stage 1, likely reflecting a smaller pool of Sertoli cells in profound HH. In IHH and CPHD boys with genital stage 1, sensitivity and specificity were 100% for INHB concentration of 35 pg/ml or less. In IHH and CPHD boys with genital stage 2, sensitivities were 86 and 80%, whereas specificities were 92% and 88%, respectively, for an INHB concentration of 65 pg/ml or less. The performance of testosterone, AMH, FSH, and LH measurements was lower. No combination or ratio of hormones performed better than INHB alone.
CONCLUSION: Discrimination of HH from CDP with baseline INHB measurement was excellent in subjects with genital stage 1 and fair in subjects with genital stage 2.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20826577     DOI: 10.1210/jc.2010-1535

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  23 in total

Review 1.  Neonatal gonadotropin therapy in male congenital hypogonadotropic hypogonadism.

Authors:  Claire Bouvattier; Luigi Maione; Jérôme Bouligand; Catherine Dodé; Anne Guiochon-Mantel; Jacques Young
Journal:  Nat Rev Endocrinol       Date:  2011-10-18       Impact factor: 43.330

Review 2.  Paediatric and adult-onset male hypogonadism.

Authors:  Andrea Salonia; Giulia Rastrelli; Geoffrey Hackett; Stephanie B Seminara; Ilpo T Huhtaniemi; Rodolfo A Rey; Wayne J G Hellstrom; Mark R Palmert; Giovanni Corona; Gert R Dohle; Mohit Khera; Yee-Ming Chan; Mario Maggi
Journal:  Nat Rev Dis Primers       Date:  2019-05-30       Impact factor: 52.329

Review 3.  Expert consensus document: European Consensus Statement on congenital hypogonadotropic hypogonadism--pathogenesis, diagnosis and treatment.

Authors:  Ulrich Boehm; Pierre-Marc Bouloux; Mehul T Dattani; Nicolas de Roux; Catherine Dodé; Leo Dunkel; Andrew A Dwyer; Paolo Giacobini; Jean-Pierre Hardelin; Anders Juul; Mohamad Maghnie; Nelly Pitteloud; Vincent Prevot; Taneli Raivio; Manuel Tena-Sempere; Richard Quinton; Jacques Young
Journal:  Nat Rev Endocrinol       Date:  2015-07-21       Impact factor: 43.330

4.  Correlation Analysis of Genotypes and Phenotypes in Chinese Male Pediatric Patients With Congenital Hypogonadotropic Hypogonadism.

Authors:  Yi Wang; Miao Qin; Lijun Fan; Chunxiu Gong
Journal:  Front Endocrinol (Lausanne)       Date:  2022-05-20       Impact factor: 6.055

5.  The E3 ubiquitin ligase RNF216/TRIAD3 is a key coordinator of the hypothalamic-pituitary-gonadal axis.

Authors:  Arlene J George; Bin Dong; Hannah Lail; Morgan Gomez; Yarely C Hoffiz; Christopher B Ware; Ning Fang; Anne Z Murphy; Erik Hrabovszky; Desiree Wanders; Angela M Mabb
Journal:  iScience       Date:  2022-05-10

6.  Serum inhibin B for differentiating between congenital hypogonadotropic hypogonadism and constitutional delay of growth and puberty: a systematic review and meta-analysis.

Authors:  Yuting Gao; Qin Du; Liyi Liu; Zhihong Liao
Journal:  Endocrine       Date:  2021-01-19       Impact factor: 3.633

7.  Congenital hypogonadotropic hypogonadism during childhood: presentation and genetic analyses in 46 boys.

Authors:  Audrey Vizeneux; Aude Hilfiger; Jérôme Bouligand; Monique Pouillot; Sylvie Brailly-Tabard; Anu Bashamboo; Ken McElreavey; Raja Brauner
Journal:  PLoS One       Date:  2013-10-24       Impact factor: 3.240

8.  GnRH receptor gene mutations in adolescents and young adults presenting with signs of partial gonadotropin deficiency.

Authors:  Johanna Hietamäki; Matti Hero; Elina Holopainen; Johanna Känsäkoski; Kirsi Vaaralahti; Anna-Pauliina Iivonen; Päivi J Miettinen; Taneli Raivio
Journal:  PLoS One       Date:  2017-11-28       Impact factor: 3.240

Review 9.  Anti-müllerian hormone and its clinical use in pediatrics with special emphasis on disorders of sex development.

Authors:  Marie Lindhardt Johansen; Casper P Hagen; Trine Holm Johannsen; Katharina M Main; Jean-Yves Picard; Anne Jørgensen; Ewa Rajpert-De Meyts; Anders Juul
Journal:  Int J Endocrinol       Date:  2013-12-03       Impact factor: 3.257

Review 10.  Serum AMH in Physiology and Pathology of Male Gonads.

Authors:  Ewa Matuszczak; Adam Hermanowicz; Marta Komarowska; Wojciech Debek
Journal:  Int J Endocrinol       Date:  2013-10-24       Impact factor: 3.257

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.